Andere Sprachen Nabriva Therapeutics plc

Aktien

A3DWGH

IE000OZRGNV6

NBRVF

Markt geschlossen - OTC Markets Andere Börsenplätze 17:34:09 25.04.2024			% 5 Tage	% 1. Jan.
0.0001 ^USD	0.00%		0.00%	+9’900.00%

2023	Nabriva Therapeutics plc meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. Juni 2023	CI
2023	Sumitomo Pharma Co., Ltd. (TSE:4506) hat von Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH und Nabriva Therapeutics Ireland Dac für 15 Millionen Dollar Vermögenswerte und Rechte an Lefamulin in China, Hongkong, Macau und Taiwan erworben.	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	19.10.23
Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index	31.07.23
Sumitomo Pharma Co., Ltd. acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.	31.07.23
Nabriva Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	24.07.23
Arbutus Biopharma Promotes Dr. Karen Sims to Chief Medical Officer, Hires Christopher Naftzger as Chief Compliance Officer	10.07.23
Nabriva Therapeutics plc Appoints H. Michael Hogan as Chief Executive Officer	07.07.23
Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer	07.07.23
Nabriva Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023	22.05.23
NABRIVA THERAPEUTICS PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	17.04.23
Nabriva Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2022	17.04.23
Nabriva Therapeutics plc Auditor Raises 'Going Concern' Doubt	17.04.23
Merck : fin de l'accord de distribution avec Nabriva	06.02.23
Nabriva Therapeutics : Material Agreement - Form 8-K	06.02.23
NABRIVA THERAPEUTICS PLC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	06.02.23
NABRIVA THERAPEUTICS PLC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	20.01.23
Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer	20.01.23
Nabriva Therapeutics : Termination of Material Agreement - Form 8-K	09.01.23
NABRIVA THERAPEUTICS PLC : Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits (form 8-K)	09.01.23
Nabriva Therapeutics Provides Corporate Update	09.01.23
Health Care Up as Biogen Rises on Alzheimer's Drug Progress -- Health Care Roundup	06.01.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Nabriva Therapeutics plc

Aktien

A3DWGH

IE000OZRGNV6

NBRVF

Andere Sprachen

Filter